The Patent Finder

Yungjin Pharmaceutical Co., Ltd.

7 patents currently held · Updated Nov 18, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

0
Ending by 2030
Dec 2033
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

No maintenance fee falls due on this company's record before Nov 18, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

PatentTitleStatus Expires Confidence
US 9,592,263Purified extract (ATC2) isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,675,658Method of treating inflammation, allergy and asthma with a purified extract (ATC2) isolated from Pseudolysimachion rotundam var. subintegrum containing abundant amount of active ingredient
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,999,646Method of treating inflammation, allergy and asthma with a purified extract (ATC1) isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient
In force
 · From the USPTO record
In forceFrom the USPTO record
US 9,655,871Composition comprising a purified extract isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom, as an active ingredient for treating a chronic obstructive pulmonary disease and the use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,046,019Purified extract (ATC1) isolated from Pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,328,110Pharmaceutical Composition for Promoting Bone Tissue Formation, Containing Stauntonia Hexaphylla Leaf Extract as Active Ingredient
In force
 · Medium confidence
In forceMedium confidence
US 10,172,816Method of treating chronic obstructive pulmonary disease (CPD) with verproside
In force
 · From the USPTO record
In forceFrom the USPTO record
Also on record, not counted in the 7: 2 lapsed for an unpaid fee · 2 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited